Contact Supplier

Contact Supplier

To get in touch with Xzencis AB, simply fill out the form below.

    Subscribe to Supplier

    Subscribe to Supplier


    Xzencis bringing Translational Safety expertise to Drug Safety Forum

    news-releasesXzencis AB
    July 1st 2024

    Mölnlycke, Sweden: – Xzencis founder Dr. Steffen Ernst will be the opening keynote speaker at the upcoming ApconiX DSF 2024 Drug Safety Forum in London.

    The forum, titled ‘A Patient First Approach to Translational Safety: From Nonclinical to Clinical’ is a free to attend, one day symposium on translational safety on October 17, 2024, hosted at the Wellcome Collection on London’s Euston Road. The event has been staged again following the success of the inaugural DSF in 2023.

    Complex safety value chain

    DSF 2024 will bring together a diverse array of industry toxicologists, patient safety and pharmacovigilance physicians and regulators to focus on Translational Safety as the complex interplay between many disciplines and functions, including nonclinical drug safety, that demand  scientific inputs complemented by effective strategies, operational setups, communication, and leadership.

    Dr. Steffen Ernst will be speaking on behalf of ApconiX, with whom Xzencis enjoys a deeply established collaborative relationship. His keynote address ‘Translational Safety Medicine by Examples’ (1000 hrs.) will highlight instances of the value of Translational Safety in practice, including showing what can happen when the critical components in its value chain fracture.

    Dr. Ernst will also chair the Expert Q&A panel session that rounds out the forum programme.

    Invitations to the event have now been issued, with those who wish to register are invited to email the organisers at: [email protected].

    About Xzencis AB

    Xzencis provides a wide suite of expert consultancy services focused on Translational Safety Solutions: planning and executing transitions and problem solving along the entire pharmaceutical value chain from pre-clinical target to market launch and beyond.

    The company’s strength is based on in-depth subject matter expertise in medicinal regulation, toxicology, clinical Patient Safety (PS) and Pharmacovigilance (PV), business administration, business development and licensing uniquely combined with hands-on business experience. These allow us to assist any life sciences company or organization with safety and regulatory issues, such as strategy development and execution, pre-clinical and clinical challenges, inbound or outbound licensing, building safety value chains, governance, Due Diligence assessments for investors and organizational design of safety departments.

    Where extra personnel are required, Xzencis can call on an extensive network of senior, experienced Toxicologists, NCDS sub-discipline experts, Safety Physicians, Safety Scientists and PV Systems experts – all with tested and proven, impeccable track records.

    Learn more at:

    About ApconiX

    Headquartered in Cheshire, in north west England, ApconiX are experts in channel biology, safety science and in all aspects of nonclinical programme design and delivery.

    Formed in 2018 by three AstraZeneca colleagues with a wide range of expertise in nonclinical drug safety, the ApconiX founding mission was to offer outsourced scientific expertise to the pharma industry and related SMEs and academic groups that require specialized services in the area of drug safety.

    The company now has a global client list and addresses all needs by providing an exceptional group of scientists to these companies, in a cost-effective and flexible way.  In this way, companies work with people they trust, to make better decisions on drug safety.

    Learn more at:


    Click on Drug Safety Forum 2024 for further information.


    Cost efficient consultants at Xzencis manage pharmaceutical product development with a focus on a integrated safety strategy with defined objectives along the pre-clinical and clinical safety value chain, saving you in the long run

    Xzencis bringing Translational Safety expertise to Drug Safety Forum
    Xzencis bringing Translational Safety expertise to Drug Safety Forum

    Keynote speaker: Xzencis founder and MD Dr. Steffen W Ernst has more than 25 years clinical and international, cross-functional experience across the entire value chain in numerous large and medium sized pharmaceutical companies.

    Contact Xzencis AB

    Simply fill out the form below to contact Xzencis AB now.

    Send Xzencis AB a Message